Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Jian Yu

Email
Center AffiliationsMolecular Therapeutics

Publications (73) (print view)

no pagination
Ali SM, Alpaugh RK, Buell JK, Stephens PJ, Yu JQ, Wu H, Hiemstra CN, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M. Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. Clin Breast Cancer. 2014 Feb;14(1):e14-6.
Ali SM, Alpaugh RK, Downing SR, Stephens PJ, Yu JQ, Wu H, Buell JK, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M. Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. J Clin Oncol. 2014 Sep;32(25):e88-91.   PMCID: 4876358
Cohen SJ, Konski AA, Putnam S, Ball DS, Meyer JE, Yu JQ, Astsaturov I, Marlow C, Dickens A, Cade DN, Meropol NJ. Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer. Br J Cancer. 2014 Jul 15;111(2):265-71.   PMCID: Pmc4102951
Doss M, Kolb HC, Walsh JC, Mocharla VP, Zhu Z, Haka M, Alpaugh RK, Chen DY, Yu JQ. Biodistribution and radiation dosimetry of the carbonic anhydrase IX imaging agent [(18) F]VM4-037 determined from PET/CT scans in healthy volunteers. Mol Imaging Biol. 2014 Oct;16(5):739-46.
Kim SP, Gross CP, Nguyen PL, Smaldone MC, Shah ND, Karnes RJ, Thompson RH, Han LC, Yu JB, Trinh QD, Ziegenfuss JY, Sun M, Tilburt JC. Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care. 2014 Jul;52(7):579-85.
Doss M, Kolb HC, Walsh JC, Mocharla V, Fan H, Chaudhary A, Zhu ZH, Alpaugh RK, Lango MN, Yu JQ. Biodistribution and Radiation Dosimetry of F-18-CP-18, a Potential Apoptosis Imaging Agent, as Determined from PET/CT Scans in Healthy Volunteers. Journal of Nuclear Medicine. 2013 Dec;54(12):2087-92.   PMCID: No NIH funds
Fourkal E, Veltchev I, Lin M, Koren S, Meyer J, Doss M, Yu JQ. 3D inpatient dose reconstruction from the PET-CT imaging of (90)Y microspheres for metastatic cancer to the liver: Feasibility study. Med Phys. 2013 Aug;40(8):081702.
Kim SP, Tilburt JC, Karnes RJ, Ziegenfuss JY, Han LC, Shah ND, Frank I, Smaldone MC, Gross CP, Yu JB, Trinh QD, Sun M, O'Malley RL, Nguyen PL. Variation in Treatment Recommendations of Adjuvant Radiation Therapy for High-risk Prostate Cancer by Physician Specialty. Urology. 2013 Oct;82(4):807-12.
Lango M, Flieder D, Arrangoiz R, Veloski C, Yu JQ, Li TY, Burtness B, Mehra R, Galloway T, Ridge JA. Extranodal Extension of Metastatic Papillary Thyroid Carcinoma: Correlation with Biochemical Endpoints, Nodal Persistence, and Systemic Disease Progression. Thyroid : official journal of the American Thyroid Association. 2013 Sep;23(9):1099-105.   PMCID: PMC 3770240
Arrangoiz R, Papavasiliou P, Stransky CA, Yu JQ, Tianyu L, Sigurdson ER, Berger AC, Farma JM. Preoperative FDG-PET/CT Is an Important Tool in the Management of Patients with Thick (T4) Melanoma. Dermatol Res Pract. 2012 Jan;2012:614349.   PMCID: PMC3359680
Doss M, Kolb HC, Zhang JJ, Belanger MJ, Stubbs JB, Stabin MG, Hostetler ED, Alpaugh RK, von Mehren M, Walsh JC, Haka M, Mocharla VP, Yu JQ. Biodistribution and Radiation Dosimetry of the Integrin Marker F-18-RGD-K5 Determined from Whole-Body PET/CT in Monkeys and Humans. Journal of Nuclear Medicine. 2012 May;53(5):787-95.
Kirchhoff T, Gaudet MM, Antoniou AC, McGuffog L, Humphreys MK, Dunning AM, Bojesen SE, Nordestgaard BG, Flyger H, Kang D, Yoo KY, Noh DY, Ahn SH, Dork T, Schurmann P, Karstens JH, Hillemanns P, Couch FJ, Olson J, Vachon C, Wang XS, Cox A, Brock I, Elliott G, Reed MW, Burwinkel B, Meindl A, Brauch H, Hamann U, Ko YD, Broeks A, Schmidt MK, van 't Veer LJ, Braaf LM, Johnson N, Fletcher O, Gibson L, Peto J, Turnbull C, Seal S, Renwick A, Rahman N, Wu PE, Yu JC, Hsiung CN, Shen CY, Southey MC, Hopper JL, Hammet F, Van Dorpe T, Dieudonne AS, Hatse S, Lambrechts D, Andrulis IL, Bogdanova N, Antonenkova N, Rogov JI, Prokofieva D, Bermisheva M, Khusnutdinova E, van Asperen CJ, Tollenaar R, Hooning MJ, Devilee P, Margolin S, Lindblom A, Milne RL, Arias JI, Zamora MP, Benitez J, Severi G, Baglietto L, Giles GG, Spurdle AB, Beesley J, Chen XQ, Holland H, Healey S, Wang-Gohrke S, Chang-Claude J, Mannermaa A, Kosma VM, Kauppinen J, Kataja V, Agnarsson BA, Caligo MA, Godwin AK, Nevanlinna H, Heikkinen T, Fredericksen Z, Lindor N, Nathanson KL, Domchek SM, Loman N, Karlsson P, Askmalm MS, Melin B, von Wachenfeldt A, Hogervorst FB, Verheus M, Rookus MA, Seynaeve C, Oldenburg RA, Ligtenberg MJ, Ausems M, Aalfs CM, Gille HJ, Wijnen JT, Garcia EB, Peock S, Cook M, Oliver CT, Frost D, Luccarini C, Pichert G, Davidson R, Chu C, Eccles D, Ong KR, Cook J, Douglas F, Hodgson S, Evans DG, Eeles R, Gold B, Pharoah PD, Offit K, Chenevix-Trench G, Easton DF. Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. Plos One. 2012 Jun;7(6):e35706.   PMCID: PMC3387216
Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M, Konski A. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma. J Gastrointest Cancer. 2012 Dec;43(4):612-8.
Konski A, Li TY, Christensen M, Cheng JD, Yu JQ, Crawford K, Haluszka O, Tokar J, Scott W, Meropol NJ, Cohen SJ, Maurer A, Freedman GM. Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in F-18-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiotherapy and Oncology. 2012 Jul;104(1):72-7.   PMCID: PMC3389132
Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012 May;119(20):4597-607.   PMCID: not NIH funded
Miller J, Doss M, McQuillen R, Shaller CC, Tolner B, Yu JQ, Chester K, Robinson MK. Impact of expression system on the function of the C6.5 diabody PET radiotracer. Tumor Biology. 2012 Jun;33(3):617-27.   PMCID: not NIH funded
Shanmugan S, Arrangoiz R, Nitzkorski JR, Yu JQ, Li TY, Cooper H, Konski A, Farma JM, Sigurdson ER. Predicting Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Using (18)FDG-PET/CT. Annals of Surgical Oncology. 2012 Jul;19(7):2178-85.
Smaldone MC, Chen DY, Yu JQ, Plimack ER. Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012 Jan;6:395-407.   PMCID: PMC3508606
Stevens KN, Fredericksen Z, Vachon CM, Wang XS, Margolin S, Lindblom A, Nevanlinna H, Greco D, Aittomaki K, Blomqvist C, Chang-Claude J, Vrieling A, Flesch-Janys D, Sinn HP, Wang-Gohrke S, Nickels S, Brauch H, Ko YD, Fischer HP, Schmutzler RK, Meindl A, Bartram CR, Schott S, Engel C, Godwin AK, Weaver J, Pathak HB, Sharma P, Brenner H, Muller H, Arndt V, Stegmaier C, Miron P, Yannoukakos D, Stavropoulou A, Fountzilas G, Gogas HJ, Swann R, Dwek M, Perkins A, Milne RL, Benitez J, Zamora MP, Perez JI, Bojesen SE, Nielsen SF, Nordestgaard BG, Flyger H, Guenel P, Truong T, Menegaux F, Cordina-Duverger E, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Sawyer E, Tomlinson I, Kerin MJ, Peto J, Johnson N, Fletcher O, Silva ID, Fasching PA, Beckmann MW, Hartmann A, Ekici AB, Lophatananon A, Muir K, Puttawibul P, Wiangnon S, Schmidt MK, Broeks A, Braaf LM, Rosenberg EH, Hopper JL, Apicella C, Park DJ, Southey MC, Swerdlow AJ, Ashworth A, Orr N, Schoemaker MJ, Anton-Culver H, Ziogas A, Bernstein L, Dur CC, Shen CY, Yu JC, Hsu HM, Hsiung CN, Hamann U, Dunnebier T, Rudiger T, Ulmer HU, Pharoah PP, Dunning AM, Humphreys MK, Wang Q, Cox A, Cross SS, Reed MW, Hall P, Czene K, Ambrosone CB, Ademuyiwa F, Hwang H, Eccles DM, Garcia-Closas M, Figueroa JD, Sherman ME, Lissowska J, Devilee P, Seynaeve C, Tollenaar R, Hooning MJ, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Winqvist R, Pylkas K, Jukkola-Vuorinen A, Grip M, John EM, Miron A, Alnaes GG, Kristensen V, Borresen-Dale AL, Giles GG, Baglietto L, McLean CA, Severi G, Kosel ML, Pankratz VS, Slager S, Olson JE, Radice P, Peterlongo P, Manoukian S, Barile M, Lambrechts D, Hatse S, Dieudonne AS, Christiaens MR, Chenevix-Trench G, Beesley J, Chen XQ, Mannermaa A, Kosma VM, Hartikainen JM, Soini Y, Easton DF, Couch FJ. 19p13.1 Is a Triple-Negative-Specific Breast Cancer Susceptibility Locus. Cancer Research. 2012 Apr;72(7):1795-803.   PMCID: PMC33199792
Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, Robinson MK. Evaluation of the Anti-HER2 C6.5 Diabody as a PET Radiotracer to Monitor HER2 status and Predict Response to Trastuzumab Treatment. Clinical Cancer Research. 2011 Mar 15;17(6):1509-20.   PMCID: PMC3060271
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Jian Yu Sparkline Graph

Graph Interactions

Co-Authors:

Similar Investigators:


Keywords (MeSH):


Last updated on Friday, December 06, 2019